J.POD® 2 EU biomanufacturing will play a key role in addressing the need for therapeutic antibodies, including those related to infectious diseases such as COVID-19
Just – Evotec Biologics’ Redmond, Washington site offers true meaning to “Facility of the Future” with flexible and podular manufacturing of clinical and commercial-stage biologics.…
Just – Evotec Biologics will manufacture anti-SARS-CoV-2 and other antibodies at its J.POD® manufacturing facility. Access to manufacturing capacity over a period of 7 years
Evotec gains access to Alloy Therapeutics’ ATX-Gx™ humanised mouse platform for biologics discovery Partnership leverages complementary strengths of in silico, in vitro and in vivo…
Just – Evotec Biologics receives grant for COVID-19 monoclonal antibody optimisation and cell line development from the COVID-19 therapeutics accelerator Grant enables the optimisation of…
Producing therapeutic antibodies is expensive and difficult, but drug-makers have unprecedented flexibility in plant design through a new modular biologics manufacturing platform that streamlines the…
Just – Evotec Biologics to provide process development and manufacturing of monoclonal antibody
Just – Evotec Biologics to provide process development required for phase I cGMP clinical manufacturing of broadly neutralising antibody against HIV
Partnership is part of a contract awarded to Ology Bioservices by the Department of Defense to develop and manufacture monoclonal antibodies for treatment and prevention…
Just – Evotec Biologics has compiled a library of a new class of humanoid antibodies using a novel, AI-derived approach. Antibodies are proteins produced and…
Read our white paper published in Drug Discovery Today
A methodology has been developed for the structural alignment and classification of full sequences from antibodies and antibody-like structures using the Antibody Structural Numbering system…